![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 13, 2022
Health care administrator Charmaine Green shares her experience supporting cancer clinical trials and discusses how her role has evolved over the years
October 13, 2022
Eight early-career investigators will present their work; two will be selected to receive awards of distinction
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
October 13, 2022
A Standing Main Member of ECOG-ACRIN since 1983
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022
This phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 24, 2022
Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022
ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma